VIA
ICPT

Virtus Investment Advisers’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Virtus Investment Advisers’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,297
Closed -$103K – 300
2023
Q2 		$103K Hold
9,297
– – 0.07% 241
2023
Q1 		$125K Buy
9,297
+935
+11% +$16.2K 0.09% 234
2022
Q4 		$103K Hold
8,362
– – 0.07% 271
2022
Q3 		$117K Buy
+8,362
New +$135K 0.05% 273

Other funds holding ICPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Virtus Investment Advisers's ICPT Position: Q3 2023 in Review

Virtus Investment Advisers sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2023, closing a stake of 9,297 shares — an estimated $103K sold.

Virtus Investment Advisers first reported a position in ICPT in Q3 2022 and held it in 4 quarters. The position peaked at $125K in Q1 2023. 146 funds tracked by Wall St. Rank hold ICPT as of Q3 2023.

  • Virtus Investment Advisers reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Virtus Investment Advisers sold 9,297 Intercept Pharmaceuticals, Inc. shares in Q3 2023, an estimated $103K.
  • Virtus Investment Advisers first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2022 and held it in 4 quarters.
  • Virtus Investment Advisers's Intercept Pharmaceuticals, Inc. position peaked at $125K in Q1 2023.
  • 146 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2023.

Based on Virtus Investment Advisers's 13F filing for Q3 2023, filed 8 Nov 2023.